Results of a Phase IIb clinical study, published in the American Journal of Ophthalmology (Ophthalmology, in press), report a 62% relative benefit for the combined… Read More »Phase IIb study of a combination therapy, comprising anti-PDGF and anti-VEGF treatments, show a 62% relative benefit over monotherapy alone
A research paper produced by a team of Google Inc. scientists, published in the Journal of the American Medical Association, has claimed that a “deep… Read More »“Deep learning” algorithm from Google demonstrates high sensitivity and specificity in diabetic retinopathy screening.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 5th, 2016 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »December 5th, 2016: “EURETINA-Brief”© Issue No. 145
Horama SAS, a gene therapy company based in Paris and specialising in the development of treatments of ophthalmic disease, has announced the receipt of €4… Read More »Paris-based gene therapy company Horama SAS raises €4M in venture capital funding for the development of retinal disease therapies.
Top-line data from a Phase IIb study of a novel integrin peptide (ALG-1001) to treat diabetic macular edema (DME) has indicated encouraging visual acuity gains,… Read More »Novel integrin peptide therapy shows non-inferiority to bevacizumab in clinical study of diabetic macular edema
A meta-analysis published in the British Journal of Ophthalmology (Br J Ophthalmol 2016;0: 1–9. doi: 10.1136/bjophthalmol-2016-309418), conducted by researchers at the Department of Ophthalmology, Second… Read More »Meta-analysis of polymorphisms in VEGF–related genes indicates positive association between a marker on VEGF-A and ranibizumab treatment.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the November 15th, 2016 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »November 15th, 2016: “EURETINA-Brief”© Issue No. 144
GenSight Biologics S.A. (Euronext: SIGHT) has announced the receipt of Orphan Drug Designation in Europe for its experimental retinitis pigmentosa (RP) treatment, “GS030”. According to… Read More »French biotechnology company GenSight receives orphan designation for retinitis pigmentosa gene therapy treatment in Europe.
Results of a multicenter, double masked phase 2 clinical trial evaluating a small protein therapy (“abicipar”), for the treatment of diabetic macular edema (DME), indicates… Read More »Novel small protein therapy shows comparable efficacy as ranibizumab in clinical study of diabetic macular edema
Research led by the University of Pisa on patients that had received implantation of the Argus II retinal prosthesis device suggest that neural plasticity in… Read More »Response to visual stimuli in Argus II implanted patients may improve with prolonged use of the device.